PT3613737T - Novo inibidor de cinase cdk9 dependente de ciclina - Google Patents

Novo inibidor de cinase cdk9 dependente de ciclina

Info

Publication number
PT3613737T
PT3613737T PT187878699T PT18787869T PT3613737T PT 3613737 T PT3613737 T PT 3613737T PT 187878699 T PT187878699 T PT 187878699T PT 18787869 T PT18787869 T PT 18787869T PT 3613737 T PT3613737 T PT 3613737T
Authority
PT
Portugal
Prior art keywords
cyclin
dependent kinase
novel inhibitor
cdk9
kinase cdk9
Prior art date
Application number
PT187878699T
Other languages
English (en)
Original Assignee
Genfleet Therapeutics Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfleet Therapeutics Shanghai Inc filed Critical Genfleet Therapeutics Shanghai Inc
Publication of PT3613737T publication Critical patent/PT3613737T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT187878699T 2017-04-19 2018-01-03 Novo inibidor de cinase cdk9 dependente de ciclina PT3613737T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710257652.7A CN108727363B (zh) 2017-04-19 2017-04-19 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂

Publications (1)

Publication Number Publication Date
PT3613737T true PT3613737T (pt) 2022-03-11

Family

ID=63856449

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187878699T PT3613737T (pt) 2017-04-19 2018-01-03 Novo inibidor de cinase cdk9 dependente de ciclina

Country Status (13)

Country Link
US (1) US10952999B2 (pt)
EP (1) EP3613737B1 (pt)
JP (1) JP6866967B2 (pt)
KR (1) KR102309986B1 (pt)
CN (1) CN108727363B (pt)
AU (1) AU2018253655B2 (pt)
BR (1) BR112019021794A2 (pt)
CA (1) CA3059622C (pt)
DK (1) DK3613737T3 (pt)
ES (1) ES2909301T3 (pt)
PT (1) PT3613737T (pt)
RU (1) RU2738654C1 (pt)
WO (1) WO2018192273A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108727363B (zh) 2017-04-19 2020-06-19 劲方医药科技(上海)有限公司 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
AU2020288270B2 (en) * 2019-06-06 2023-07-13 Genfleet Therapeutics (Shanghai) Inc. Polymorph of CDK9 inhibitor and preparation method for polymorph and use thereof
WO2020259556A1 (zh) * 2019-06-27 2020-12-30 南京明德新药研发有限公司 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
US20230219961A1 (en) 2020-05-12 2023-07-13 Suzhou Alphama Biotechnology Co., Ltd. Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof
WO2021227904A1 (zh) * 2020-05-12 2021-11-18 苏州阿尔脉生物科技有限公司 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
TWI809330B (zh) * 2020-11-20 2023-07-21 大陸商勁方醫藥科技(上海)有限公司 Cdk9抑制劑的多晶型物及其製法和用途
CN116270644A (zh) * 2023-05-22 2023-06-23 劲方医药科技(上海)有限公司 Cdk9抑制剂与bcl-2抑制剂联用的药物组合及其用途
CN116270658B (zh) * 2023-05-24 2023-10-27 劲方医药科技(上海)有限公司 Cdk9抑制剂与btk抑制剂联用的药物组合及其用途
CN116496267B (zh) * 2023-06-26 2023-09-22 劲方医药科技(上海)有限公司 Cdk9抑制剂及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3745227B2 (ja) * 1998-11-16 2006-02-15 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 両耳信号処理技術
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2-取代的4-杂芳基-嘧啶、其组合物及其用途
CA2445348A1 (en) * 2001-04-27 2002-11-07 Mitsubishi Pharma Corporation Novel benzylpiperidine compound
AU2007249891A1 (en) * 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Selective inhibitors of ROCK protein kinase and uses thereof
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
EP2668162A1 (en) * 2011-01-28 2013-12-04 Novartis AG Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
GB201206908D0 (en) * 2012-04-19 2012-06-06 Cancer Rec Tech Ltd Therapeutic compounds
CN108727363B (zh) 2017-04-19 2020-06-19 劲方医药科技(上海)有限公司 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂

Also Published As

Publication number Publication date
US10952999B2 (en) 2021-03-23
CA3059622C (en) 2021-09-07
AU2018253655B2 (en) 2020-12-17
WO2018192273A1 (zh) 2018-10-25
AU2018253655A1 (en) 2019-10-17
ES2909301T3 (es) 2022-05-06
KR20200039616A (ko) 2020-04-16
CN108727363B (zh) 2020-06-19
US20200078343A1 (en) 2020-03-12
EP3613737A1 (en) 2020-02-26
JP2020517595A (ja) 2020-06-18
EP3613737A4 (en) 2020-08-26
RU2738654C1 (ru) 2020-12-15
JP6866967B2 (ja) 2021-04-28
CA3059622A1 (en) 2018-10-25
BR112019021794A2 (pt) 2020-05-05
DK3613737T3 (da) 2022-03-07
KR102309986B1 (ko) 2021-10-12
EP3613737B1 (en) 2021-12-29
CN108727363A (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
IL292422A (en) Cyclin-dependent kinase 7 (cdk7) inhibitors
HRP20190039T1 (hr) Inhibitori ciklin-ovisne kinaze 7 (cdk7)
HK1245260A1 (zh) 細胞週期蛋白依賴性激酶7(cdk7)的抑制劑
HK1246645A1 (zh) 細胞周期蛋白依賴性激酶的抑制劑
IL282737A (en) Cyclin-dependent kinase 7 (CDK7) inhibitors
PT3613737T (pt) Novo inibidor de cinase cdk9 dependente de ciclina
IL279791A (en) Inhibitors of cyclin-dependent kinases
SG11202004918XA (en) Amino-fluoropiperidine derivative as kinase inhibitor
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
IL275207A (en) An oxyfluoropiperidine derivative as a kinase inhibitor
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
GB201705201D0 (en) Novel compounds and their use as kinase inhibitors
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors